| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615749 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 28 Pages |
Abstract
Our results have demonstrated that ER is an important clinical indicator of patients at high risk. As applications of novel agents evolve, further studies are required to tailor therapy for this patient group.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Holly Lee, Peter Duggan, Ahsan Chaudhry, Paola Neri, Jason Tay, Fariborz Rashid-Kolvear, Nizar J. Bahlis, Victor H. Jimenez-Zepeda,